CRISPR Therapeutics AG (CRSP) Cash Flow Statement
CRISPR Therapeutics AG (CRSP) generated -$369.6M of operating cash flow over the twelve months to 2026-06-30, spent $1.7M on capital expenditure and had free cash flow of -$371.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRSPCRISPR Therapeutics AGFollow CRSP — free
—
Price chart with a free account
- Market cap
- 4.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.06 | -0.07 | -0.10 | 0.06 | -0.24 | 0.54 | -0.50 | -0.26 | -0.14 | -0.35 | -0.37 | |
| Capital expenditure | 0.00 | 0.01 | 0.00 | 0.01 | 0.02 | 0.08 | 0.04 | 0.01 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | -0.06 | -0.08 | -0.10 | 0.05 | -0.26 | 0.46 | -0.53 | -0.27 | -0.14 | -0.35 | -0.37 | |
| Share repurchases | — | — | 0.00 | — | — | — | — | — | — | — | — | |
| Stock-based compensation | 0.01 | 0.02 | 0.03 | 0.04 | 0.07 | 0.10 | 0.10 | 0.08 | 0.09 | 0.07 | — |
USD billions · SEC XBRL
CRISPR Therapeutics AG — questions
- What is CRISPR Therapeutics AG's operating cash flow?
- -$369.6M over the twelve months to 2026-06-30.
- How much does CRISPR Therapeutics AG spend on capital expenditure?
- $1.7M over the twelve months to 2026-06-30.
- What is CRISPR Therapeutics AG's free cash flow?
- -$371.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from CRISPR Therapeutics AG's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.